Depression FDA - Search News

FDA Approves ‘Spravato’ Nasal Spray

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

CNN on MSN · 1d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

TMJ418h

FDA approves standalone nasal spray to treat depression

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

17hon MSN

TTUHSC Psychiatry chairman discusses newly approved antidepressant nasal spray

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...

39mon MSN

Pregnancy raises risks to mental health in MS patients, study says

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

FDA Approves ‘Spravato’ Nasal Spray

Trending now